Get startedLog in
    Picture of Crinetics Pharmaceuticals logo

    CRNX — Crinetics Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

    Picture of Crinetics Pharmaceuticals logoCrinetics Pharmaceuticals
    26/09/2024 21:09
    Sept 26 (Reuters) - Crinetics Pharmaceuticals Inc
 CRNX.O :
    * CRINETICS SUBMITS NEW DRUG APPLICATION FOR PALTUSOTINE FOR
THE
TREATMENT OF ACROMEGALY
    * CRINETICS PHARMACEUTICALS INC - PHASE 3 STUDIES MET ALL
PRIMARY
AND SECONDARY ENDPOINTS
    * CRINETICS PHARMACEUTICALS INC - FDA NOTIFICATION ON NDA
STATUS
EXPECTED IN DECEMBER

Source text for Eikon:  ID:nGNX1MRXSS 
Further company coverage:  CRNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Crinetics Pharmaceuticals

    See all news